Indirubin-3′-monoxime exerts a dual mode of inhibition towards leukotriene-mediated vascular smooth muscle cell migration

Cardiovascular Research

Volumn 101, Issue 3, 2014, Pages 522-532

  Blažević, Tina ^a   Schaible, Anja M ^b   Weinhäupl, Katharina ^a   Schachner, Daniel ^a   Nikels, Felix ^b   Weinigel, Christina ^b   Barz, Dagmar ^b   Atanasov, Atanas G ^a   Pergola, Carlo ^b   Werz, Oliver ^b   Dirsch, Verena M ^a   Heiss, Elke H ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

5 Lipoxygenase; Indirubin 3 monoxime; Leukotrienes; Migration; Vascular smooth muscle cells

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CYSTEINE; CYSTEINYL-LEUKOTRIENE; INDIRUBIN 3' MONOXIME; INDIRUBIN-3'-MONOXIME; INDOLE DERIVATIVE; LEUKOTRIENE; OXIME; PEPTIDOLEUKOTRIENE; PLATELET DERIVED GROWTH FACTOR;

5-LIPOXYGENASE; ARTICLE; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; FEMALE; HUMAN; INDIRUBIN-3′-MONOXIME; MALE; METABOLISM; MIGRATION; NEOINTIMA; PHYSIOLOGY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELLS;

5-LIPOXYGENASE; INDIRUBIN-3′-MONOXIME; LEUKOTRIENES; MIGRATION; VASCULAR SMOOTH MUSCLE CELLS;

ARACHIDONATE 5-LIPOXYGENASE; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CYSTEINE; FEMALE; HUMANS; INDOLES; LEUKOTRIENES; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; OXIMES; PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84894597398     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt339     Document Type: Article

References (40)

1. Schwaiberger AV, Heiss EH, Cabaravdic M, Oberan T, Zaujec J, Schachner D et al. Indirubin-3′-monoxime blocks vascular smooth muscle cell proliferation by inhibition of signal transducer and activator of transcription 3 signaling and reduces neointima formation in vivo. Arterioscler Thromb Vasc Biol 2010;30:2475-2481.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
3. Back M. Inflammatory signaling through leukotriene receptors in atherosclerosis. Curr Atheroscler Rep 2008;10:244-251.
4. Hlawaty H, Jacob MP, Louedec L, Letourneur D, Brink C, Michel JB et al. Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis. Arterioscler Thromb Vasc Biol 2009;29:518-524.
5. Peters-Golden M, HendersonWRJr. Leukotrienes. N Engl J Med 2007;357:1841-1854.
6. Zhao L, Funk CD. Lipoxygenase pathways in atherogenesis. Trends Cardiovasc Med 2004; 14:191-195.
7. Sparrow CP, Parthasarathy S, Steinberg D. Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification. J Lipid Res 1988;29:745-753.
8. Parthasarathy S, Wieland E, Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci USA 1989;86: 1046-1050.
9. Folcik VA, Nivar-Aristy RA, Krajewski LP, Cathcart MK. Lipoxygenase contributes to the oxidation of lipids inhuman atherosclerotic plaques. J Clin Invest 1995;96:504-510.
10. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003;100:1238-1243.
11. Jessup W, Darley-Usmar V, O'Leary V, Bedwell S. 5-lipoxygenase is not essential in macrophage-mediated oxidation of low-density lipoprotein. Biochem J 1991;278(Pt 1): 163-169.
12. Folcik VA, Cathcart MK. Assessment of 5-lipoxygenase involvement in human monocyte-mediated LDL oxidation. J Lipid Res 1993;34:69-79.
13. Pergola C, Dodt G, Rossi A, Neunhoeffer E, Lawrenz B, Northoff H et al. Erk-mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma. Proc Natl Acad Sci USA 2008;105:19881-19886.
14. Pergola C, Rogge A, Dodt G, Northoff H, Weinigel C, Barz D et al. Testosterone suppresses phospholipase D, causing sex differences in leukotriene biosynthesis in human monocytes. FASEB J 2011;25:3377-3387.
15. Sroka IM, Heiss EH, Havlicek L, Totzke F, Aristei Y, Pechan P et al. A novel roscovitine derivative potently induces G1-phase arrest in platelet-derived growth factor-BBactivated vascular smooth muscle cells. Mol Pharmacol 2010;77:255-261.
16. Shin S, Wakabayashi J, Yates MS, Wakabayashi N, Dolan PM, Aja S et al. Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. Eur J Pharmacol 2009;620:138-144.
17. Roos TU, Heiss EH, Schwaiberger AV, Schachner D, Sroka IM, Oberan T et al. Caffeic acid phenethyl ester inhibits PDGF-induced proliferation of vascular smooth muscle cells via activation of p38 MAPK, HIF-1a, and heme oxygenase-1. J Nat Prod 2011;74: 352-356.
18. Fischer L, Szellas D, Radmark O, Steinhilber D, Werz O. Phosphorylation-and stimulusdependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors. FASEB J 2003;17:949-951.
19. Koeberle A, Siemoneit U, Bühring U, Northoff H, Laufer S, AlbrechtWet al. Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J Pharmacol Exp Ther 2008;326:975-982.
20. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: Subsets and functions. Nat Rev Cardiol 2010;7:77-86.
21. Cheng C, Haasdijk RA, Tempel D, den Dekker WK, Chrifi I, Blonden LA et al. PDGF-induced migration of vascular smooth muscle cells is inhibited by heme oxygenase-1 via VEGFR2 upregulation and subsequent assembly of inactive VEGFR2/PDGFRb heterodimers. Arterioscler Thromb Vasc Biol 2012;32:1289-1298.
22. Chen S, Ding Y, Tao W, Zhang W, Liang T, Liu C. Naringenin inhibits TNF-a induced VSMC proliferation and migration via induction of HO-1. Food Chem Toxicol 2012;50: 3025-3031.
23. Rodriguez AI, Gangopadhyay A, Kelley EE, Pagano PJ, Zuckerbraun BS, Bauer PM. HO-1 and CO decrease platelet-derived growth factor-induced vascular smooth muscle cell migration via inhibition of Nox1. Arterioscler Thromb Vasc Biol 2010;30:98-104.
24. Drummond GS, Kappas A. Prevention of neonatal hyperbilirubinemia by tin protoporphyrin IX, a potent competitive inhibitor of heme oxidation. Proc Natl Acad Sci 1981;78: 6466.
25. Zhang J, Ohta T, Maruyama A, Hosoya T, Nishikawa K, Maher JM et al. BRG1 interacts with Nrf2 to selectively mediate HO-1 induction in response to oxidative stress. Mol Cell Biol 2006;26:7942-7952.
26. Kim JK, Park GM. Indirubin-3-monoxime exhibits anti-inflammatory properties by down-regulating NF-kappaB and JNK signaling pathways in lipopolysaccharide-treated RAW264.7 cells. Inflamm Res 2012;61:319-325.
27. Tateson JE, RandallRW, Reynolds CH, JacksonWP, Bhattacherjee P, Salmon JA et al. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo. Br J Pharmacol 1988;94:528-539.
28. Blazevic T, Schwaiberger AV, Schreiner CE, Schachner D, Schaible AM, Grojer CS et al. 12/15-Lipoxygenase contributes to platelet-derived growth factor-induced activation of signal transducer and activator of transcription 3. J Biol Chem 2013;288:35592-35603.
29. Kaetsu Y, Yamamoto Y, Sugihara S, MatsuuraT, Igawa G, Matsubara K et al. Role of cysteinyl leukotrienes in the proliferation and the migration of murine vascular smooth muscle cells in vivo and in vitro. Cardiovasc Res 2007;76:160-166.
30. Chan KH, Ng MK, Stocker R. Haem oxygenase-1 and cardiovascular disease: mechanisms and therapeutic potential. Clin Sci (Lond) 2011;120:493-504.
31. Niture SK, Jain AK, Shelton PM, Jaiswal AK. Src subfamily kinases regulate nuclear export and degradation of transcription factor Nrf2 to switch off Nrf2-mediated antioxidant activation of cytoprotective gene expression. J Biol Chem 2011;286:28821-28832.
32. Rojo AI, Medina-Campos ON, Rada P, Zúñiga-Toalá A, López-Gazcón A, Espada S et al. Signaling pathways activated by the phytochemical nordihydroguaiaretic acid contribute to a Keap1-independent regulation of Nrf2 stability: Role of glycogen synthase kinase-3. Free Radic Biol Med 2012;52:473-487.
33. Polychronopoulos P, Magiatis P, Skaltsounis AL, Myrianthopoulos V, Mikros E, Tarricone A et al. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem 2004; 47:935-946.
34. Nam S, Buettner R, Turkson J, Kim D, Cheng JQ, Muehlbeyer S et al. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci USA 2005;102:5998-6003.
35. Ra°dmark O, Werz O, Steinhilber D, Samuelsson B. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 2007;32:332-341.
36. Allen S, Dashwood M, Morrison K, Yacoub M. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 1998;97:2406-2413.
37. Michelassi F, Landa L, Hill RD, Lowenstein E, Watkins WD, Petkau AJ et al. Leukotriene D4: a potent coronary artery vasoconstrictor associated with impaired ventricular contraction. Science 1982;217:841-843.
38. Dahlen SE, Bjork J, Hedqvist P, Arfors KE, Hammarstrom S, Lindgren JA et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA 1981;78:3887-3891.
39. Palmberg L, Claesson HE, Thyberg J. Leukotrienes stimulate initiation of DNA synthesis in cultured arterial smooth muscle cells. J Cell Sci 1987;88:151-159.
40. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Freeman A, Showell HJ. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 2002;22:443-449.